Description
InformationML385 ML385 is a novel and specific NRF2 inhibitor with an IC50 of 1.9 µM. It inhibits the downstream target gene expression of NRF2. NRF2 regulates the activity of several ferroptosis and lipid peroxidation-related proteins.In vitroML385 shows anti-tumor activity in NSCLC (subcutaneous and orthotopic NSCLC models) both as a single agent and in combination with carboplatin. The PK profile tested in CD-1 mice shows that ML385 has a half-life (t1/2 = 2.82 h) after IP injection (30 mg/kg). ML385 could alleviate the pancreatic injury.In vivoCell Datacell lines：Rat leukemic cell lines RCL/0, RO/1 and K7 and human myelomonocytic leukemic U937Concentrations：5 µMIncubation Time：24, 48 and 72 hPowder Purity:≥99%